Clinical and laboratory baseline characteristics of patients with POEMS
| . | All, N = 59 (%) . | No progression, N = 45 (%) . | Progression, N = 14 (%) . | P . |
|---|---|---|---|---|
| Median age at diagnosis, y (range) | 50 (20-70) | 51 (20-70) | 42 (36-59) | .02 |
| Median age at transplantation, y (range) | 51 (20-70) | 52 (20-70) | 46 (36-59) | .01 |
| Time to transplantation from diagnosis, mo (range) | 4.9 (2.4-261) | 5.2 (2.4-261) | 4.1 (3-122) | |
| Male sex | 38 (64) | 28 (62) | 10 (71) | |
| White race | 49 (83) | 36 (80) | 13 (93) | |
| ECOG PS 2/3 | 41 (70) | 34 (76) | 7 (50) | |
| Polyneuropathy | 57 (97) | 44 (98) | 13 (93) | |
| Organomegaly | 39 (66) | 32 (73) | 7 (50) | |
| Endocrinopathy | 53 (90) | 43 (96) | 10 (71) | |
| Monoclonal plasma cell disorder* | 58 (98) | 44 (98) | 14 (100) | |
| Skin changes | 54 (92) | 44 (98) | 10 (71) | |
| Extravascular fluid overload | 53 (90) | 43 (96) | 10 (71) | |
| Castleman disease | 11 (19) | 8 (18) | 3 (21) | |
| Plasma VEGF level at transplantation (normal 31-86 pg/mL) | 452 | 436 (N = 33) | 555 (N = 8) | |
| IQR | 232-788 | 206-788 | 369-794 | |
| Ig heavy chain | ||||
| IgA | 32 (54) | 28 (62) | 4 (29) | |
| IgG | 17 (29) | 9 (20) | 8 (57) | .0008 |
| IgM | 2 (3) | 2 (4) | 0 | |
| Biclonal (IgG + IgA) | 1 (2) | 1 (2) | 0 | |
| No heavy chain | 7 (12) | 5 (11) | 2 (14) | |
| Ig light chain | ||||
| Lambda | 56 (95) | 42 (93) | 14 (100) | |
| Kappa | 3 (5) | 3 (7) | 0 | |
| BM involvement by monoclonal plasma cells, % | ||||
| ≥ 10% | 11 (19) | 7 (16) | 4 (29) | |
| 5%-9% | 11 (19) | 10 (22) | 1 (7) | |
| < 5% | 17 (29) | 12 (26) | 5 (35) | |
| Polytypic plasma cell aggregates | 20 (34) | 16 (36) | 4 (29) | |
| Pretransplantation PET/CT scan with increased FDG uptake | 18 (31) | 10 (42) | 8 (80) | .03 |
| (Baseline PET/CT scan performed, N = 34) | (N = 24) | (N = 10) | ||
| Previous treatment | ||||
| None | 25 (42) | 20 (44) | 5 (36) | |
| Previous chemotherapy | 28 (47) | 20 (44) | 8 (57) | |
| Cyclophosphamide-based | 14 | 10 | 4 | |
| Melphalan-based | 2 | 0 | 2 | |
| IMID | 9 | 6 | 3 | |
| Others | 13 | 12 | 1 | |
| Previous radiotherapy | 10 (17) | 8 (18) | 2 (14) |
| . | All, N = 59 (%) . | No progression, N = 45 (%) . | Progression, N = 14 (%) . | P . |
|---|---|---|---|---|
| Median age at diagnosis, y (range) | 50 (20-70) | 51 (20-70) | 42 (36-59) | .02 |
| Median age at transplantation, y (range) | 51 (20-70) | 52 (20-70) | 46 (36-59) | .01 |
| Time to transplantation from diagnosis, mo (range) | 4.9 (2.4-261) | 5.2 (2.4-261) | 4.1 (3-122) | |
| Male sex | 38 (64) | 28 (62) | 10 (71) | |
| White race | 49 (83) | 36 (80) | 13 (93) | |
| ECOG PS 2/3 | 41 (70) | 34 (76) | 7 (50) | |
| Polyneuropathy | 57 (97) | 44 (98) | 13 (93) | |
| Organomegaly | 39 (66) | 32 (73) | 7 (50) | |
| Endocrinopathy | 53 (90) | 43 (96) | 10 (71) | |
| Monoclonal plasma cell disorder* | 58 (98) | 44 (98) | 14 (100) | |
| Skin changes | 54 (92) | 44 (98) | 10 (71) | |
| Extravascular fluid overload | 53 (90) | 43 (96) | 10 (71) | |
| Castleman disease | 11 (19) | 8 (18) | 3 (21) | |
| Plasma VEGF level at transplantation (normal 31-86 pg/mL) | 452 | 436 (N = 33) | 555 (N = 8) | |
| IQR | 232-788 | 206-788 | 369-794 | |
| Ig heavy chain | ||||
| IgA | 32 (54) | 28 (62) | 4 (29) | |
| IgG | 17 (29) | 9 (20) | 8 (57) | .0008 |
| IgM | 2 (3) | 2 (4) | 0 | |
| Biclonal (IgG + IgA) | 1 (2) | 1 (2) | 0 | |
| No heavy chain | 7 (12) | 5 (11) | 2 (14) | |
| Ig light chain | ||||
| Lambda | 56 (95) | 42 (93) | 14 (100) | |
| Kappa | 3 (5) | 3 (7) | 0 | |
| BM involvement by monoclonal plasma cells, % | ||||
| ≥ 10% | 11 (19) | 7 (16) | 4 (29) | |
| 5%-9% | 11 (19) | 10 (22) | 1 (7) | |
| < 5% | 17 (29) | 12 (26) | 5 (35) | |
| Polytypic plasma cell aggregates | 20 (34) | 16 (36) | 4 (29) | |
| Pretransplantation PET/CT scan with increased FDG uptake | 18 (31) | 10 (42) | 8 (80) | .03 |
| (Baseline PET/CT scan performed, N = 34) | (N = 24) | (N = 10) | ||
| Previous treatment | ||||
| None | 25 (42) | 20 (44) | 5 (36) | |
| Previous chemotherapy | 28 (47) | 20 (44) | 8 (57) | |
| Cyclophosphamide-based | 14 | 10 | 4 | |
| Melphalan-based | 2 | 0 | 2 | |
| IMID | 9 | 6 | 3 | |
| Others | 13 | 12 | 1 | |
| Previous radiotherapy | 10 (17) | 8 (18) | 2 (14) |
Statistically significant factors are shown with P values.
ECOG indicates Eastern Cooperative Oncology Group; PS, performance score; IQR, interquartile range; PET, positron emission tomography; FDG, fluorodeoxyglucose; IMID, immunomodulatory agents (thalidomide, lenalidomide); and others, rituximab, vincristine, adriamycin, azathioprine, mycophenolate mofetil, interferon, tamoxifen, infliximab.
M-protein in serum, urine, or plasmacytoma.